Dynamic Capital Management Ltd cut its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 94.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,895 shares of the biopharmaceutical company’s stock after selling 62,725 shares during the period. Dynamic Capital Management Ltd’s holdings in Gilead Sciences were worth $279,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of the business. Keel Point LLC lifted its holdings in shares of Gilead Sciences by 0.4% in the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 12 shares in the last quarter. National Asset Management Inc. lifted its holdings in shares of Gilead Sciences by 0.7% in the second quarter. National Asset Management Inc. now owns 26,270 shares of the biopharmaceutical company’s stock valued at $1,862,000 after purchasing an additional 174 shares in the last quarter. Linscomb & Williams Inc. lifted its holdings in shares of Gilead Sciences by 10.1% in the second quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock valued at $411,000 after purchasing an additional 531 shares in the last quarter. Heritage Wealth Advisors lifted its holdings in shares of Gilead Sciences by 2.5% in the fourth quarter. Heritage Wealth Advisors now owns 26,523 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 642 shares in the last quarter. Finally, Hanson & Doremus Investment Management lifted its holdings in shares of Gilead Sciences by 35.7% in the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 648 shares in the last quarter. Hedge funds and other institutional investors own 78.35% of the company’s stock.
In other news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.51, for a total value of $2,087,750.00. Following the transaction, the executive vice president now owns 62,738 shares of the company’s stock, valued at $5,239,250.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now directly owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. Insiders sold 308,600 shares of company stock worth $24,328,226 in the last ninety days. 1.16% of the stock is owned by company insiders.
Shares of NASDAQ GILD opened at $74.69 on Tuesday. The company has a market cap of $98,075.59, a price-to-earnings ratio of 8.73, a price-to-earnings-growth ratio of -1.73 and a beta of 1.18. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the previous year, the business earned $2.70 earnings per share. The business’s revenue was down 18.7% compared to the same quarter last year. analysts anticipate that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were given a $0.57 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 3.05%. Gilead Sciences’s dividend payout ratio is presently 26.64%.
GILD has been the topic of a number of recent research reports. Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 target price (down previously from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the company a “hold” rating in a research report on Wednesday, January 3rd. Finally, Wells Fargo raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $79.02 to $96.00 in a research report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $88.61.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences (GILD) Holdings Trimmed by Dynamic Capital Management Ltd” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/gilead-sciences-gild-holdings-trimmed-by-dynamic-capital-management-ltd.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.